Market Access – Connecting Medicines with Healthcare Systems
Contents
What does market access mean?
Market access is the planning and implementation of conditions under which a medicine or medical service can reach its intended patients within a healthcare system. It includes reimbursement, funding, assessment and practical availability.
The term differs from marketing authorization. Authorization addresses different questions from assessment of additional benefit or decisions about reimbursement conditions. Procedures and responsibilities also vary between countries and product categories.
Why does market access matter to pharmaceutical companies?
A product can only be used in routine care when relevant organizational and financial conditions are addressed. Companies therefore need an early understanding of the evidence required by decision-makers and the actual unmet needs in care.
Communication has a particular responsibility here. Clinical findings, patient-relevant outcomes and economic questions should be distinguished clearly. A potential commercial advantage is not evidence of clinical benefit, and a persuasive presentation cannot replace suitable supporting data.
Which activities does market access involve?
A useful approach connects evidence planning with understanding of the relevant healthcare system.
- Analyze the setting: Identify authorization pathways, assessment procedures, payers and the practical care context.
- Define evidence needs: Consider appropriate comparisons, populations and patient-relevant outcomes early.
- Develop a value account: Assemble data, assumptions and limitations in suitable supporting materials.
- Support implementation: Translate assessment results, reimbursement agreements and practical access conditions into subsequent planning.
In Germany, early benefit assessment and subsequent reimbursement negotiations are particularly relevant for many new active substances. Exceptions and special procedures require separate assessment rather than assuming a single route applies to every product.
What communication challenges arise?
The requirements of different countries and payers cannot always be addressed through the same document. A global value argument often requires local adaptation and review of the evidence supporting it.
Marketing teams should also distinguish authorization status, an assessment outcome and the conditions under which a medicine may be prescribed or reimbursed. These concepts are not interchangeable. Collaboration with Medical Affairs and other specialists helps maintain precise statements and make uncertainty visible.
Distinguish European assessment from national decisions
Since January 2025, specified new cancer medicines and advanced therapy medicinal products have entered EU joint clinical assessment. These assessments support national HTA procedures. They do not establish a single European price or shared reimbursement decision. Market access therefore needs to address both European evidence requirements and subsequent national assessment and financing questions.
Conclusion: Connect evidence with the conditions for care
Market access examines how a product can reach patients within a healthcare system. Appropriate evidence, system knowledge and clear accountability are central. Pharmaceutical communication should explain both medical value and access conditions accurately and understandably.
